re: smart money moving into biotechs retro applying PE is diffuclt with resources in a boom forward looking PEs could be better value than historic but it needs to reflect a deeper understanding of boom and "bust" resource cycles.
Biotechs lack scale and are to fragmented to be the subject of overall high PE ratios as in the US - same applies to local tech stocks.
Scale makes a big difference to stability in PE and profits
smart money moving into biotechs, page-21
Add ASX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$65.57 |
Change
0.370(0.57%) |
Mkt cap ! $12.71B | |||
| Open | High | Low | Value | Volume |
| $65.64 | $66.07 | $65.15 | $10.96M | 166.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 344 | $65.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $65.63 | 593 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| ASX (ASX) Chart |